CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression

Open access

Published version of a preprint

Abstract

Background: Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge. Objective: To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones. Methods: Using data from the Parkinson’s Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains (“walking and balance”; “motor complications”; “cognition”; “autonomic dysfunction”; “functional dependence”; “activities of daily living”). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression. Results: Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age ( p < 0.0001), greater MDS-UPDRS total scores ( p < 0.0001), higher GDS-15 depression scores ( p = 0.0341), lower dopamine transporter binding ( p = 0.0043), and lower CSF total α-synuclein levels ( p = 0.0030). Symptomatic treatment was not significantly associated with reaching a milestone ( p = 0.1639). Conclusion: Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jpd-223433

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Kaplan-Meier curves of progression-free survival, as defined by reaching any progression milestone, based on data collected at 12, 24, 36, 48, and 60 months (blue) versus 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months (red). Each curve reflects de novo PD participants who were milestone-free at baseline and completed at least one of the corresponding follow-up visits.
Fig. 1 Kaplan-Meier curves of progression-free survival, as defined by reaching any progression milestone, based on data collected at 12, 24, 36, 48, and 60 months (blue) versus 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months (red). Each curve reflects de novo PD participants who were milestone-free at baseline and completed at least one of the corresponding follow-up visits.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 5

  1. Fahn S, 1987, Recent Dev Parkinsons Dis, 2, 153
  2. Poewe W, 2006, J Neurol, 253, VII2
  3. McDermott MP, 1995, Arch Neurol, 52, 565
  4. Kang JH, 2013, JAMA Neurol, 70, 1277
  5. Food and Drug Administration, 2017, Multiple endpoints in clinical trials: Guidance for industry

Cited by

See all 87

Metadata

Authors
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., Merchant, K., Arnedo, V., Hutten, S. J., O’Grady, A. N., Poston, K. L., Tanner, C. M., Weintraub, D., Kieburtz, K., Marek, K., Coffey, C. S., & Initiative, O. B. O. T. P. P. M.
Affiliations
  • University of Iowa (US)
  • University of Pennsylvania (US)
  • Northwestern University (US)
  • Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
  • University of Pittsburgh (US)
  • Universitätsmedizin Göttingen (DE)
  • Indiana University Indianapolis (US)
  • University of California San Diego (US)
  • Michael J. Fox Foundation (US)
  • Stanford Medicine (US)
  • San Francisco VA Medical Center (US)
  • Philadelphia VA Medical Center (US)
  • University of Rochester Medicine (US)
  • Institute for Neurodegenerative Disorders (US)
Corresponding author
Brumm, Michael C.
Venue
Journal of Parkinson’s Disease
Published
2023-07-12
Volume
13
Issue
6
Pages
899-916
ISSN
  • 1877-7171 (ISSN-L)
  • 1877-718X
OpenAlex
W4384301272
Cited by
70
References
58
Citations by year
2026: 25 · 2025: 27 · 2024: 17 · 2023: 1
FWCI
11.85
Type
journal article
Language
en
Open access
Locations
  • Journal of Parkinson s Disease (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Funders
  • U.S. Department of Defense
  • U.S. Department of Veterans Affairs
  • Michael J. Fox Foundation for Parkinson's Research
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Biogen
  • CHDI Foundation
  • Teva Pharmaceutical Industries
  • Celgene
  • University of Pennsylvania
  • University of Pittsburgh
  • International Parkinson and Movement Disorder Society
  • Demensförbundet
  • Jazz Pharmaceuticals
  • Parkinson's Foundation
  • Acorda Therapeutics
  • Neurocrine Biosciences
  • Verily Life Sciences
  • Voyager Therapeutics
  • Deutsche Forschungsgemeinschaft
  • Eisai
  • Servier
  • H. Lundbeck A/S
  • Sun Pharma
  • Deutsche Parkinson Vereinigung
  • National Institutes of Health
  • Genentech
  • Allergan
  • Sanofi Genzyme
  • Avid Radiopharmaceuticals
  • National Institute of Neurological Disorders and Stroke
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease progression, Parkinson's Progression Markers Initiative, de novo Parkinson's disease, predictors of progression, motor complications, cognitive impairment, functional dependence, autonomic dysfunction, activities of daily living, depression, dopamine transporter imaging, MDS-UPDRS, symptomatic treatment, disability
MeSH terms
Cognition, Humans, Parkinson Disease, Biomarkers, Disease Progression, Primary Dysautonomias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. https://app.cochat.ai/papers/10.3233/jpd-223433
The paper
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., Merchant, K., Arnedo, V., Hutten, S. J., O’Grady, A. N., Poston, K. L., Tanner, C. M., Weintraub, D., Kieburtz, K., Marek, K., . . . Initiative, O. B. O. T. P. P. M. (2023). Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-223433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.